Expanding Access to Life-Changing Treatments for Rare Diseases
We announced a bilateral agreement with the Government of Nova Scotia, investing over $39 million to improve access to new and existing treatments for rare diseases. This funding will help ensure that more people living with rare conditions get the medications, early diagnosis, and screening they need.
Through this agreement, we are supporting access to six important drugs, including treatments for lymphomas, von Hippel-Lindau disease, neurofibromatosis type 1, and hyperoxaluria type 1. More medications will continue to be added as price negotiations are finalized.
Beyond treatments, this partnership also focuses on improving early diagnosis and screening—because timely access to care can make all the difference for individuals and families affected by rare diseases.
The Government of Canada remains committed to working with provinces and territories to ensure that Canadians, no matter where they live, have better access to the care they need.
NATIONAL PHARMACARE: I want you to know that our Government remains deeply committed to national pharmacare and we will continue negotiating with provinces and territories to move this forward.